C07D 239/36
As doubly bound oxygen atom or as unsubstituted hydroxy radical
Official title: as doubly bound oxygen atom or as unsubstituted hydroxy radical
C07D239/36 (As doubly bound oxygen atom or as unsubstituted hydroxy radical) appears on 451 US grants and 318 published applications in this corpus.
Search patents in C07D- Granted patents
- 451
- Published applications
- 318
- Assignees
- 242
- Inventors
- 1,302
- Latest grant
- 16 Jun 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1976 | 8 | 0 |
| 1977 | 13 | 0 |
| 1978 | 3 | 0 |
| 1979 | 6 | 0 |
| 1980 | 5 | 0 |
| 1981 | 8 | 0 |
| 1982 | 8 | 0 |
| 1983 | 5 | 0 |
| 1984 | 3 | 0 |
| 1985 | 6 | 0 |
| 1986 | 9 | 0 |
| 1987 | 9 | 0 |
| 1988 | 5 | 0 |
| 1989 | 9 | 0 |
| 1990 | 4 | 0 |
| 1991 | 10 | 0 |
| 1992 | 10 | 0 |
| 1993 | 10 | 0 |
| 1994 | 13 | 0 |
| 1995 | 15 | 0 |
| 1996 | 8 | 0 |
| 1997 | 3 | 0 |
| 1998 | 11 | 0 |
| 1999 | 9 | 0 |
| 2000 | 11 | 0 |
| 2001 | 3 | 1 |
| 2002 | 7 | 7 |
| 2003 | 10 | 8 |
| 2004 | 6 | 13 |
| 2005 | 5 | 21 |
| 2006 | 4 | 5 |
| 2007 | 7 | 10 |
| 2008 | 6 | 8 |
| 2009 | 11 | 19 |
| 2010 | 8 | 18 |
| 2011 | 8 | 8 |
| 2012 | 16 | 18 |
| 2013 | 17 | 14 |
| 2014 | 14 | 19 |
| 2015 | 18 | 13 |
| 2016 | 13 | 17 |
| 2017 | 20 | 22 |
| 2018 | 13 | 14 |
| 2019 | 9 | 8 |
| 2020 | 11 | 17 |
| 2021 | 9 | 12 |
| 2022 | 11 | 13 |
| 2023 | 8 | 11 |
| 2024 | 7 | 13 |
| 2025 | 3 | 7 |
| 2026 | 6 | 2 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Inhibitors of ret16 Jun 2026US 12,655,128 B2Rigel Pharmaceuticals, Inc.
- Histone deacetylase inhibitors26 May 2026US 12,637,433 B2The University of Queensland
- Pyrimidinone compounds and uses thereof19 May 2026US 12,630,554 B2Hutchison Medipharma Limited
- 4-((6-oxopyrimidin-1(6H)-yl)methyl)benzoic acid as an inducer of Z A1AT secretion for treating AATD12 May 2026US 12,624,008 B2Centessa Pharmaceuticals (UK) Limited
- Sigma-1 receptor ligands and therapeutic uses thereof28 Apr 2026US 12,612,371 B2Centre National De La Recherche Scientifique
- Compositions Comprising a Retinoid X Receptor (RXR) Agonist, a Retinoic Acid Receptor (RAR) Agonist, or a Dual RXR/RAR Agonist16 Apr 2026US 2026/0103445 A1Arizona Board of Regents on behalf of Arizona State University
- 3,4-alkoxy Substituted Phenethyl Lactam Compound, Preparation Method therefor, and Use Thereof5 Feb 2026US 2026/0035349 A1Guangzhou Chia Tai Innovative Pharmaceutical Co., Ltd.
- Heteroaryl compounds for the treatment of pain25 Dec 2025US 2025/0388543 A1Vertex Pharmaceuticals Incorporated
- Pyrimidine derivative6 Nov 2025US 2025/0340557 A1Aska Pharmaceutical Co., Ltd.
- Gonadotropin-releasing hormone receptor antagonists and methods relating thereto11 Sep 2025US 2025/0282792 A1Neurocrine Biosciences, Inc.
Most cited
By later US patents
- Electrophilic polyethylene oxides for the modification of polysaccharides, polypeptides (proteins) and surfaces208US 5,650,234 ASurface Engineering Technologies, Division of Innerdyne, Inc. · 1997
- Mediators of hedgehog signaling pathways, compositions and uses related thereto127US 6,545,005 B1Curtis, Inc. · 2003
- Modulators of ATP-binding cassette transporters109US 8,642,609 B2Vertex Pharmaceuticals Incorporated · 2014
- 2-arylpyrimidines and herbicidal use thereof87US 5,300,477 ARohm and Haas Company · 1994
- 7-substituted tetracycline compounds84US 6,818,635 B2Paratek Pharmaceuticals, Inc. · 2004